Environmental Exposures and Health: Exploration of Non-Traditional Settings, (R01)

This grant opportunity encourages interdisciplinary research aimed at promoting health, limiting symptoms and disease, and reducing health disparities in children and older adults living or spending time in non-traditional settings. These settings result in exposure to environmental pollutants and toxins that result in health risks, symptoms, and other health conditions/diseases including lower respiratory diseases, chronic obstructive pulmonary disease, and cardiovascular diseases. Risk identification and symptom management include prevention and behavior changes and actions to maintain health and prevent disease with an emphasis on the individual, family, and community which will advance nursing science. 


For purposes of this FOA, non-traditional settings, for children and older adults, include, but are not limited to places such as community centers, pre-school and non-traditional school environments (e.g., churches, daycare, home-based schools, dormitories, and alternative schools), child and older adult foster care facilities, older adult day care facilities, half-way homes,  assisted living and long-term care facilities.    


Budget: Not limited (but must reflect actual needs), 5 year project period.
Deadlines: 5 June 2012, 5 October 2012, and more


For more information, see: http://grants.nih.gov/grants/guide/pa-files/PA-12-133.html

NIH Technology-Based Interventions to Promote Engagement in Care and Treatment Adherence for Substance Abusing Populations with HIV (R01)

This grant seeks applications to test the utility and implementation of technological tools, including mobile devices, to promote engagement in Human Immunodeficiency Virus (HIV) care among substance abusing populations with HIV. Research projects may focus on (a) the use of technology to directly improve patient-level outcomes (i.e., adherence); (b) the capacity of HIV treatment providers and related service delivery organizations to adopt and integrate such technologies to promote HIV treatment outcomes; or (c) the use of technology to improve the organization and delivery of HIV treatment and services.


Budget: Not limited (must reflect actual needs) over 5 years.
Deadlines: 7 May 2012, 7 September 2012, and more.


See http://grants.nih.gov/grants/guide/pa-files/PA-12-117.html for more details.

MARIE CURIE INTERNATIONAL INCOMING FELLOWSHIPS (IIF)

MARIE CURIE INTERNATIONAL INCOMING FELLOWSHIPS (IIF) Identifier: FP7-PEOPLE-2012-IIF

International Incoming Fellowships are designed to give researchers from outside of Europe an opportunity to work on research projects in Europe. This helps to develop research cooperation between Europe and other parts of the world to everybody’s benefit.

International Incoming Fellowships are directed exclusively at experienced researchers, namely those who either:

1.    have at least 4 years of research experience (full-time equivalent) after obtaining the degree which would formally entitle them to embark on a doctorate either in the country in which the degree was obtained or in the country in which the research will be carried out; or

2.    are already in possession of a doctoral degree (PhD).

All Marie Curie Actions have a bottom-up approach, i.e. all fields of research of interest to the European Union are eligible for funding. All research carried out must respect fundamental ethics principles (see also the Ethics part of the Guide for Applicants).

The time limit to fulfill one of these conditions is the deadline for proposal submission of the relevant call.

The required research experience does not include breaks during the research career.

Deadline:  16 August 2012 at 17:00:00 (Brussels local time)

Budget: € 40 000 000

For further information, see: http://ec.europa.eu/research/participants/portal/page/people?callIdentifier=FP7-PEOPLE-2012-IIF

NIH Partnerships for Interventions to Treat Chronic, Persistent and Latent Infections (R21/R33)

This grant opportunity seeks to stimulate basic and early-stage translational research focused on development of novel intervention strategies to clear persistent, chronic or latent infectious agents from the host. Responsive applications will define and address a therapeutic need specific to a targeted pathogen.    

Examples of possible intervention strategies include, but are not limited to:

• Targeting pathogen latency establishment and/or maintenance mechanisms;
• Targeting mechanisms enabling pathogen evasion of host immune responses;
• Enhancing pathogen susceptibility to existing interventions;
• Modulation of pathogen-specific immune cells;
• Restoration and/or enhancement of specific aspects of the immune system
• Targeting of specific metabolic sub-populations responsible for chronic infections
• Eliminating replication competent viral nucleic acids from infected cells

The grant is worth $275,000 for the first two years, and then an additional $300,000 per year for three years for a total of $1,175,000.

A letter of intent must be submitted by June 13, 2012.  The full application should be submitted by July 13, 2012.

For more information, see http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-12-020.html

Grand Challenges Explorations Round 9

Grand Challenges Explorations, an initiative to encourage innovative and unconventional global health and development solutions, is now accepting grant proposals for its latest application round.  Applicants can be at any experience level; in any discipline; and from any organization, including colleges and universities, government
laboratories, research institutions, non-profit organizations and for profit companies.


Proposals are being accepted online until May 15, 2012 on the following topics:

 * New Approaches for the Interrogation of Anti-malarial Compounds
 * Aid is Working. Tell the World
 * Design New Approaches to Optimize Immunization Systems
 * Explore New Solutions in Global Health Priority Areas
 * Protect Crop Plants from Biotic Stresses From Field to Market


(please see this link for more information about each topic: http://www.grandchallenges.org/Explorations/Pages/TopicsOverview.aspx)

Initial grants will be US $100,000 each, and projects showing promise will have the opportunity to receive additional funding of up to US $1 million.

Partnerships for Development of Vaccine Technologies (R01)

Partnerships for Development of Vaccine Technologies (R01)

This Funding Opportunity Announcement (FOA) issued by the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), invites research applications for projects focused on preclinical development of candidate technologies (including adjuvants) that would improve vaccine effectiveness and/or simplify vaccine delivery to patient populations during a natural outbreak of an infectious disease or following the intentional release of an infectious agent. Applications must include a Product Development Strategy attachment and demonstrate substantive investment by at least one industrial participant.  

Letter of intent due date: May 26, 2012  

Award budget: Budgets for direct costs of up to $750,000 per year may be requested. In addition, applicants may request up to a total of $300,000 for major equipment in the first year of the award to ensure that research aims can be met and biohazards can be contained.

Scope of the proposed project should determine the project period. The maximum period is 5 years. 

For further information, see: http://grants.nih.gov/grants/guide/rfa-files/RFA-AI-12-014.html

Resource Access for the Bridging Interventional Development Gaps Program (X01)

Resource Access for the Bridging Interventional Development Gaps Program (X01)

The high cost of translating therapeutic discoveries into clinically-available agents can deter the development of promising therapeutics. When private sector resources are limited, BrIDGs’ in-kind services could help researchers span the gap between the preclinical and clinical stages of therapy development and continue to evaluate agents that may improve the standard of care for patients with a variety of diseases and disorders. The purpose of this Funding Opportunity Announcement (FOA) is to invite investigators to apply for access to government-funded contract resources needed for the preclinical development of therapeutic agents.

Applications are accepted for the development of the following therapeutic agents:

• Small molecules
• Peptides
• Oligonucleotides
• Gene vectors
• Recombinant proteins
• Monoclonal antibodies

Potential therapies for any disease or disorder may be submitted. Vaccines, devices and diagnostic agents are ineligible for the program. Only lead agents with demonstrated pharmacological activity in an appropriate disease model will be considered for development.

Application open date: March 3, 2012

For further information, see: http://grants.nih.gov/grants/guide/pa-files/PAR-12-092.html